Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26172950 | 0.89 | KCNH2 (0.39) | KCNH2THRBGLO1NPC1MEN1 | |
| SCHEMBL23964331 | 0.79 | ALDH1A1 (0.40) | KCNH2THRBMAPT | |
| SCHEMBL26172960 | 0.76 | THRB (0.44) | KCNH2THRBGLO1NPC1RAB9A | |
| SCHEMBL30277702 | 0.76 | GLO1 (0.41) | KCNH2THRBGLO1NPC1RAB9A | |
| SCHEMBL26172959 | 0.75 | KCNH2 (0.45) | KCNH2THRBGLO1NPC1RAB9A | |
| SCHEMBL23964481 | 0.75 | ALDH1A1 (0.40) | THRBKMT2AMAPT | |
| Scarlet Red SCHEMBL62339 | 0.68 | THRB (0.72) | THRBGLO1NPC1RAB9AMEN1 | |
| Scarlet Red SCHEMBL29493283 | 0.68 | THRB (0.72) | THRBGLO1NPC1RAB9AMEN1 | |
| Scarlet Red SCHEMBL6833437 | 0.68 | THRB (0.72) | THRBGLO1NPC1RAB9AMEN1 | |
| Scarlet Red SCHEMBL1070583 | 0.68 | THRB (0.72) | THRBGLO1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | MAP1LC3B, MAP1LC3A, SQSTM1 | KCNH2 4876/4885THRB 1791/4885GLO1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.